{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:29:05Z","timestamp":1726100945081},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"DOI":"10.1186\/s12887-024-05048-8","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T07:02:40Z","timestamp":1726038160000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An evaluation of the empirical vancomycin dosing guide in pediatric cardiology"],"prefix":"10.1186","volume":"24","author":[{"given":"Yousif S.","family":"Alakeel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazeed","family":"Alahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghadah","family":"Alanazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bushra","family":"Alawbathani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kadi","family":"Alshutwi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meshary","family":"Almeshary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahad","family":"Aldhahri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meshal","family":"Alshakrah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"5048_CR1","doi-asserted-by":"publisher","unstructured":"Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children [published correction appears in Clin Infect Dis. 2011;53(3):319]. Clin Infect Dis. 2011;52(3):e18-e55. https:\/\/doi.org\/10.1093\/cid\/ciq146","DOI":"10.1093\/cid\/ciq146"},{"issue":"11","key":"5048_CR2","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/phar.2019","volume":"37","author":"CA Thomas","year":"2017","unstructured":"Thomas CA, Picone A, Menon S, Willis BC. Empirical vancomycin dosing in Pediatric patients with congenital heart Disease and the impact of cardiopulmonary bypass on trough concentrations. Pharmacotherapy. 2017;37(11):1341\u20136. https:\/\/doi.org\/10.1002\/phar.2019.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"5048_CR3","first-page":"21","volume":"31","author":"JH Martin","year":"2010","unstructured":"Martin JH, Norris R, Barras M, et al. Therapeutic monitoring of Vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the society of infectious diseases pharmacists. Clin Biochem Rev. 2010;31(1):21\u20134.","journal-title":"Clin Biochem Rev"},{"issue":"6","key":"5048_CR4","doi-asserted-by":"publisher","first-page":"416","DOI":"10.4212\/cjhp.v67i6.1403","volume":"67","author":"J Hoang","year":"2014","unstructured":"Hoang J, Dersch-Mills D, Bresee L, Kraft T, Vanderkooi OG. Achieving therapeutic Vancomycin levels in pediatric patients. Can J Hosp Pharm. 2014;67(6):416\u201322. https:\/\/doi.org\/10.4212\/cjhp.v67i6.1403.","journal-title":"Can J Hosp Pharm"},{"issue":"5","key":"5048_CR5","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/INF.0b013e3181906e40","volume":"28","author":"A Frymoyer","year":"2009","unstructured":"Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. Current recommended dosing of Vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J. 2009;28(5):398\u2013402. https:\/\/doi.org\/10.1097\/INF.0b013e3181906e40.","journal-title":"Pediatr Infect Dis J"},{"key":"5048_CR6","doi-asserted-by":"publisher","first-page":"470364","DOI":"10.1155\/2011\/470364","volume":"2011","author":"L Broome","year":"2011","unstructured":"Broome L, So TY. An evaluation of initial Vancomycin dosing in infants, children, and adolescents. Int J Pediatr. 2011;2011:470364. https:\/\/doi.org\/10.1155\/2011\/470364.","journal-title":"Int J Pediatr"},{"issue":"5","key":"5048_CR7","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1345\/aph.1P588","volume":"45","author":"LS Eiland","year":"2011","unstructured":"Eiland LS, English TM, Eiland EH 3rd. Assessment of Vancomycin dosing and subsequent serum concentrations in pediatric patients. Ann Pharmacother. 2011;45(5):582\u20139. https:\/\/doi.org\/10.1345\/aph.1P588.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"5048_CR8","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jmii.2015.08.027","volume":"50","author":"D Hwang","year":"2017","unstructured":"Hwang D, Chiu NC, Chang L, et al. Vancomycin dosing and target attainment in children. J Microbiol Immunol Infect. 2017;50(4):494\u20139. https:\/\/doi.org\/10.1016\/j.jmii.2015.08.027.","journal-title":"J Microbiol Immunol Infect"},{"issue":"6","key":"5048_CR9","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1542\/hpeds.2014-0019","volume":"4","author":"LM Geerlof","year":"2014","unstructured":"Geerlof LM, Boucher J. Evaluation of Vancomycin dosing and corresponding drug concentrations in pediatric patients. Hosp Pediatr. 2014;4(6):342\u20137. https:\/\/doi.org\/10.1542\/hpeds.2014-0019.","journal-title":"Hosp Pediatr"},{"issue":"1","key":"5048_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1053\/jcrc.2000.0150001","volume":"15","author":"ML Glover","year":"2000","unstructured":"Glover ML, Cole E, Wolfsdorf J. Vancomycin dosage requirements among pediatric intensive care unit patients with normal renal function. J Crit Care. 2000;15(1):1\u20134. https:\/\/doi.org\/10.1053\/jcrc.2000.0150001.","journal-title":"J Crit Care"},{"issue":"3","key":"5048_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/cid\/cir034","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant SStaphylococcusaureus infection in adults and children. Clin Infect Dis. 2011;52(3):1\u201338.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"5048_CR12","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1097\/INF.0b013e318286378e","volume":"32","author":"J Le","year":"2013","unstructured":"Le J, Bradley JS, Murray W, et al. Improved Vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J. 2013;32(4):e155\u201363. https:\/\/doi.org\/10.1097\/INF.0b013e318286378e.","journal-title":"Pediatr Infect Dis J"},{"key":"5048_CR13","doi-asserted-by":"crossref","unstructured":"Rybak M, et al. Vancomycin Pharmacokinetics in burn patients and intravenous drug abusers. Antimicrobial Agents and Chemotherapy; may 1990. pp. 792\u20135.","DOI":"10.1128\/AAC.34.5.792"},{"key":"5048_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/clpt.1988.105","volume":"44","author":"JC Garrelts","year":"1988","unstructured":"Garrelts JC, Peterie JD. Altered Vancomycin dose vs. serum concentration relationship in burn patients. Clin Pharmacol ther. 1988;44:9\u201313.","journal-title":"Clin Pharmacol ther"},{"issue":"9","key":"5048_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3390\/children4090079","volume":"4","author":"H Orr","year":"2017","unstructured":"Orr H, Trone D, Elder J, Raj A. Assessment of initial vancomycin dosing in Pediatric Oncology patients. Children. 2017;4(9):79. https:\/\/doi.org\/10.3390\/children4090079.","journal-title":"Children"},{"issue":"3","key":"5048_CR16","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1177\/1078155215591386","volume":"22","author":"O Abdel Hadi","year":"2015","unstructured":"Abdel Hadi O, Al Omar S, Nazer L, Mubarak S, Le J. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients. J Oncol Pharm Pract. 2015;22(3):448\u201353. https:\/\/doi.org\/10.1177\/1078155215591386.","journal-title":"J Oncol Pharm Pract"},{"key":"5048_CR17","doi-asserted-by":"publisher","unstructured":"Shahrami, et al. Achievement of Vancomycin Therapeutic goals in critically ill patients: early individualization may be beneficial. Critical Care Research and Practice. Article ID. Volume 2016;1245815:7. https:\/\/doi.org\/10.1155\/2016\/1245815.","DOI":"10.1155\/2016\/1245815"},{"key":"5048_CR18","doi-asserted-by":"crossref","unstructured":"Marlowe KF, et al. An Assessment of Vancomycin Pharmacokinetic Variability in Pediatric Cardiology patients. J Pediatr Pharmacol Ther. 2003;8:132\u20137.","DOI":"10.5863\/1551-6776-8.2.132"},{"issue":"6","key":"5048_CR19","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/PCC.0000000000002918","volume":"23","author":"PT Scully","year":"2022","unstructured":"Scully PT, Lam WM, Coronado Munoz AJ, Modem VM. Augmented renal clearance of Vancomycin in suspected Sepsis: Single-Center, Retrospective Pediatric Cohort. Pediatr Crit Care Med. 2022;23(6):444\u201352. https:\/\/doi.org\/10.1097\/PCC.0000000000002918.","journal-title":"Pediatr Crit Care Med"},{"issue":"9","key":"5048_CR20","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s40262-018-0636-7","volume":"57","author":"I Bilbao-Meseguer","year":"2018","unstructured":"Bilbao-Meseguer I, Rodr\u00edguez-Gasc\u00f3n A, Barrasa H, Isla A, Solin\u00eds M\u00c1. Augmented renal clearance in critically ill patients: a systematic review. Clin Pharmacokinet. 2018;57(9):1107\u201321. https:\/\/doi.org\/10.1007\/s40262-018-0636-7.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"5048_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.00897-21","volume":"65","author":"CY He","year":"2021","unstructured":"He CY, Ye PP, Liu B, Song L, van den Anker J, Zhao W. Population pharmacokinetics and dosing optimization of Vancomycin in infants, children, and adolescents with augmented renal clearance. Antimicrob Agents Chemother. 2021;65(10):10\u2013128. https:\/\/doi.org\/10.1128\/AAC.00897-21.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"5048_CR22","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.21037\/tau-20-1048","volume":"9","author":"J He","year":"2020","unstructured":"He J, Yang ZT, Qian X, Zhao B, Mao EQ, Chen EZ, Bian XL. A higher dose of Vancomycin is needed in critically ill patients with augmented renal clearance. Transl Androl Urol. 2020;9(5):2166\u201371. https:\/\/doi.org\/10.21037\/tau-20-1048.","journal-title":"Transl Androl Urol"},{"issue":"19","key":"5048_CR23","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1001\/archinte.166.19.2138","volume":"166","author":"L Hidayat","year":"2006","unstructured":"Hidayat L, Hsu D, Quist R, Shriner K, Wong-Beringer A. High-dose vancomycin therapy for Methicillin-Resistant Staphylococcus aureus infections. Arch Intern Med. 2006;166(19):2138. https:\/\/doi.org\/10.1001\/archinte.166.19.2138.","journal-title":"Arch Intern Med"},{"issue":"12","key":"5048_CR24","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.amjmed.2010.07.025","volume":"123","author":"L Pritchard","year":"2010","unstructured":"Pritchard L, Baker C, Leggett J, Sehdev P, Brown A, Bayley K. Increasing vancomycin serum trough concentrations and incidence of Nephrotoxicity. Am J Med. 2010;123(12):1143\u20139. https:\/\/doi.org\/10.1016\/j.amjmed.2010.07.025.","journal-title":"Am J Med"},{"issue":"6","key":"5048_CR25","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.clinthera.2007.06.014","volume":"29","author":"M Jeffres","year":"2007","unstructured":"Jeffres M, Isakow W, Doherty J, Micek S, Kollef M. A retrospective analysis of possible renal toxicity associated with Vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther. 2007;29(6):1107\u201315. https:\/\/doi.org\/10.1016\/j.clinthera.2007.06.014.","journal-title":"Clin Ther"},{"issue":"7","key":"5048_CR26","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1097\/inf.0000000000001882","volume":"37","author":"T Fiorito","year":"2018","unstructured":"Fiorito T, Luther M, Dennehy P, LaPlante K, Matson K. Nephrotoxicity with Vancomycin in the Pediatric Population. Pediatr Infect Dis J. 2018;37(7):654\u201361. https:\/\/doi.org\/10.1097\/inf.0000000000001882.","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"5048_CR27","doi-asserted-by":"publisher","first-page":"e0202439","DOI":"10.1371\/journal.pone.0202439","volume":"13","author":"B Moffett","year":"2018","unstructured":"Moffett B, Morris J, Kam C, Galati M, Dutta A, Akcan-Arikan A. Vancomycin associated acute kidney injury in pediatric patients. PLoS ONE. 2018;13(10):e0202439. https:\/\/doi.org\/10.1371\/journal.pone.0202439.","journal-title":"PLoS ONE"},{"issue":"2","key":"5048_CR28","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1128\/aac.01568-12","volume":"57","author":"S van Hal","year":"2012","unstructured":"van Hal S, Paterson D, Lodise T. Systematic review and Meta-analysis of Vancomycin-Induced Nephrotoxicity Associated with Dosing schedules that maintain troughs between 15 and 20 milligrams per Liter. Antimicrob Agents Chemother. 2012;57(2):734\u201344. https:\/\/doi.org\/10.1128\/aac.01568-12.","journal-title":"Antimicrob Agents Chemother"},{"key":"5048_CR29","doi-asserted-by":"publisher","unstructured":"Tongsai S, Koomanachai P. The safety and efficacy of high versus low Vancomycin trough levels in the treatment of patients with infections caused by methicillin-resistant Staphylococcus aureus: a meta-analysis. BMC Res Notes. 2016;9(1). https:\/\/doi.org\/10.1186\/s13104-016-2252-7.","DOI":"10.1186\/s13104-016-2252-7"},{"issue":"3","key":"5048_CR30","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jpeds.2010.08.019","volume":"158","author":"S McKamy","year":"2011","unstructured":"McKamy S, Hernandez E, Jahng M, Moriwaki T, Deveikis A, Le J. Incidence and risk factors influencing the development of Vancomycin Nephrotoxicity in Children. J Pediatr. 2011;158(3):422\u20136. https:\/\/doi.org\/10.1016\/j.jpeds.2010.08.019.","journal-title":"J Pediatr"},{"issue":"6","key":"5048_CR31","doi-asserted-by":"publisher","first-page":"e20162423","DOI":"10.1542\/peds.2016-2423","volume":"139","author":"M Miloslavsky","year":"2017","unstructured":"Miloslavsky M, Galler M, Moawad I, Actis J, Cummings B, El Saleeby C. The impact of Pediatric-Specific Vancomycin Dosing guidelines: a Quality Improvement Initiative. Pediatrics. 2017;139(6):e20162423. https:\/\/doi.org\/10.1542\/peds.2016-2423.","journal-title":"Pediatrics"},{"key":"5048_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.1","volume":"2","author":"JA Kellum","year":"2012","unstructured":"Kellum JA, Lameire N, Aspelin P, et al. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney inter Suppl. 2012;2:1\u2013138.","journal-title":"Kidney inter Suppl"},{"issue":"2","key":"5048_CR33","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s00467-005-2105-4","volume":"21","author":"N Chen","year":"2006","unstructured":"Chen N, Aleksa K, Woodland C, Rieder M, Koren G. Ontogeny of drug elimination by the human kidney. Pediatr Nephrol. 2006;21(2):160\u20138. https:\/\/doi.org\/10.1007\/s00467-005-2105-4.","journal-title":"Pediatr Nephrol"},{"issue":"9","key":"5048_CR34","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/BF02002914","volume":"155","author":"J Sonntag","year":"1996","unstructured":"Sonntag J, Prankel B, Waltz S. Serum creatinine concentration, urinary creatinine excretion and creatinine clearance during the first 9 weeks in preterm infants with a birth weight below 1500\u00a0g. Eur J Pediatr. 1996;155(9):815\u20139. https:\/\/doi.org\/10.1007\/BF02002914.","journal-title":"Eur J Pediatr"},{"key":"5048_CR35","volume-title":"Costanzo Physiology Seventh edn","author":"LS Costanzo","year":"2022","unstructured":"Costanzo LS. Cardiovascular physiology. Costanzo Physiology Seventh edn. Amsterdam, The Netherlands: Elsevier; 2022."},{"issue":"2","key":"5048_CR36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/cpt.3095","volume":"115","author":"Y Shimamoto","year":"2024","unstructured":"Shimamoto Y, Fukushima K, Mizuno T, Ichikawa H, Kurosaki K, Maeda S, Okuda M. Model-informed Vancomycin Dosing optimization to address delayed renal maturation in infants and Young children with critical congenital heart disease. Clin Pharmacol Ther. 2024;115(2):239\u201347. https:\/\/doi.org\/10.1002\/cpt.3095.","journal-title":"Clin Pharmacol Ther"},{"key":"5048_CR37","doi-asserted-by":"crossref","unstructured":"Garc\u00eda MP, Marti-Bonmati E, Guevara JG, Gomez IG. Alteration of vancomycin pharmacokinetics during cardiopulmonary bypass in patients undergoing cardiac surgery. American Journal of Health-System Pharmacy [Internet]. 2003 Feb 1 [cited 2021 Aug 30];60(3):260\u20135. https:\/\/academic.oup.com\/ajhp\/article\/60\/3\/260\/5143039","DOI":"10.1093\/ajhp\/60.3.260"},{"issue":"6","key":"5048_CR38","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1089\/sur.2014.198","volume":"16","author":"SW Davies","year":"2015","unstructured":"Davies SW, Efird JT, Guidry CA, Dietch ZC, Willis RN, Shah PM, et al. Vancomycin-Associated Nephrotoxicity: the obesity factor. Surg Infect. 2015;16(6):684\u201393. Epub 2015\/09\/02. pmid:26324996; PubMed Central PMCID: PMCPMC4663651.","journal-title":"Surg Infect"},{"key":"5048_CR39","doi-asserted-by":"crossref","unstructured":"Knoderer CA, Nichols KR, Lyon KC, Veverka MM, Wilson AC. Are Elevated Vancomycin Serum Trough Concentrations Achieved Within the First 7 Days of Therapy Associated with Acute Kidney Injury in Children? Journal of the Pediatric Infectious Diseases Society. 2014;3(2):127\u201331. Epub 2014\/06\/01. pmid:26625365.","DOI":"10.1093\/jpids\/pit076"},{"key":"5048_CR40","doi-asserted-by":"crossref","unstructured":"Hammoud K, Brimacombe M, Yu A, Goodloe N, Haidar W, El Atrouni W. Vancomycin Trough and Acute Kidney Injury: A Large Retrospective, Cohort Study. American journal of nephrology. 2016;44(6):456\u201361. Epub 2016\/10\/28. pmid:27788522.","DOI":"10.1159\/000452427"},{"issue":"1","key":"5048_CR41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1611391","volume":"376","author":"A Kaddourah","year":"2017","unstructured":"Kaddourah A, Basu RK, Bagshaw SM, Goldstein SL. Epidemiology of Acute kidney Injury in critically ill children and young adults. N Engl J Med. 2017;376(1):11\u201320. Epub 2016\/12\/14. pmid:27959707; PubMed Central PMCID: PMCPMC5322803.","journal-title":"N Engl J Med"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-024-05048-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-024-05048-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-024-05048-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T07:06:50Z","timestamp":1726038410000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-024-05048-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5048"],"URL":"https:\/\/doi.org\/10.1186\/s12887-024-05048-8","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"assertion":[{"value":"19 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board (study number SP18\/197\/R) at the King Abdullah International Medical Research Center (KAIMRC). Informed consent was waived off by the KAIMRC institutional review board. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"575"}}